Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 28, 2021 USD ($) shares	Feb. 28, 2021 shares	Jun. 30, 2021 shares	Mar. 31, 2021 USD ($) shares	Jun. 30, 2022 shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 shares	Jun. 02, 2021
Stock Purchase Agreement and Series X Preferred Stock
Net proceeds from issuance of private placement | $						$ 104,261
Beneficial conversion feature | $				$ 19,565
Common Stock Issuable Upon Conversion at Transaction Date		14,813,954
Minimum
Stock Purchase Agreement and Series X Preferred Stock
Common stock, percentage of beneficial ownership initially, after conversion					4.99%
Common stock, percentage of beneficial ownership thereafter, after conversion					4.99%
Maximum
Stock Purchase Agreement and Series X Preferred Stock
Common stock, percentage of beneficial ownership initially, after conversion					9.99%
Common stock, percentage of beneficial ownership thereafter, after conversion					19.99%
Shares issued in merger
Stock Purchase Agreement and Series X Preferred Stock
Common Stock Issuable Upon Conversion at Transaction Date		8,417,502
Shares issued in February 2021 Financing
Stock Purchase Agreement and Series X Preferred Stock
Common Stock Issuable Upon Conversion at Transaction Date		5,928,952
Warrants assumed in merger
Stock Purchase Agreement and Series X Preferred Stock
Common Stock Issuable Upon Conversion at Transaction Date		467,500
Series X redeemable convertible preferred stock
Stock Purchase Agreement and Series X Preferred Stock
Issuance of preferred stock in a private offering of public equity, net of issuance costs (in shares)				35,573
Number of shares of common stock into which each share of Series X Preferred Stock may be converted					166.67
Series X Preferred Stock at Transaction Date		88,882
Common Stock Issuable Upon Conversion at Transaction Date					5,242,501
Number of preferred shares converted during period					54,622
Preferred stock, outstanding (in shares)					31,455		31,455
Series X redeemable convertible preferred stock | Shares issued in merger
Stock Purchase Agreement and Series X Preferred Stock
Series X Preferred Stock at Transaction Date		50,504
Series X redeemable convertible preferred stock | Shares issued in February 2021 Financing
Stock Purchase Agreement and Series X Preferred Stock
Series X Preferred Stock at Transaction Date		35,573
Series X redeemable convertible preferred stock | Warrants assumed in merger
Stock Purchase Agreement and Series X Preferred Stock
Series X Preferred Stock at Transaction Date		2,805
Common stock
Stock Purchase Agreement and Series X Preferred Stock
Number of shares of common stock into which each share of Series X Preferred Stock may be converted					166.67			166.67
Common Stock Issuable Upon Conversion at Transaction Date					5,242,501
Number of common shares issued from conversion of Series X preferred shares			8,921,966		9,103,664
Quellis Biosciences, Inc | Stock Purchase Agreement
Stock Purchase Agreement and Series X Preferred Stock
Beneficial conversion feature | $	$ 19,600
Quellis Biosciences, Inc | Series X redeemable convertible preferred stock
Stock Purchase Agreement and Series X Preferred Stock
Number of shares of common stock into which each share of Series X Preferred Stock may be converted	166.67
Quellis Biosciences, Inc | Series X redeemable convertible preferred stock | Stock Purchase Agreement
Stock Purchase Agreement and Series X Preferred Stock
Issuance of preferred stock in a private offering of public equity, net of issuance costs (in shares)	35,573
Gross proceeds from issuance of preferred stock in a private offering | $	$ 110,000
Net proceeds from issuance of private placement | $	104,300
Issuance costs | $	$ 5,700
Quellis Biosciences, Inc | Common stock | Series X redeemable convertible preferred stock
Stock Purchase Agreement and Series X Preferred Stock
Number of shares of common stock into which each share of Series X Preferred Stock may be converted	166.67